- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.10. | GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes | ||
| 30.10. | Eli Lilly's tirzepatide products come up more than $1B short of expectations in Q3 | ||
| 30.10. | AstraZeneca's China president faces 'ongoing investigation' by authorities in the country | ||
| 30.10. | Sage discontinues Zulresso, drops pair of pipeline prospects as it creeps toward 2026 cash cliff | ||
| 30.10. | With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end | ||
| 29.10. | Novartis' Scemblix leaps into newly diagnosed leukemia-where winning over doctors may take time | ||
| 29.10. | Modified dosing regimen of Eli Lilly's Alzheimer's drug leads to significant reduction in brain swelling | ||
| 29.10. | Bristol Myers partner Zai Lab plots KarXT filing in China after trial win | ||
| 29.10. | Protega scores FDA nod for new dosage of abuse-deterrent opioid Roxybond | ||
| 29.10. | Novartis' Pluvicto enters FDA orbit for expansion bid as agency requests 'flexibility' | ||
| 29.10. | Pfizer bumps up revenue outlook by $1.5B in Paxlovid rebound amid criticism from activist investor Starboard | ||
| 29.10. | Merck KGaA's MilliporeSigma production push rolls on with $76M ADC plant investment | ||
| 28.10. | After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME | ||
| 28.10. | Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay | ||
| 28.10. | Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease | ||
| 28.10. | Fog clears to reveal Parabilis, a rebranded cancer biotech with big name backers | ||
| 28.10. | Pfizer, seeking to equalize outcomes, taps Patrick Dempsey to shepherd cancer patients to resources | ||
| 25.10. | After prior rejection, Iterum nabs long-sought FDA nod for oral UTI drug Orlynvah | ||
| 25.10. | Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382% | ||
| 25.10. | J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups | ||
| 25.10. | BeiGene, ex-AstraZeneca exec faces investigation in China: reports | ||
| 25.10. | UK health secretary warns GLP-1s not for 'body beautiful picture for Instagram' amid misuse concerns | ||
| 24.10. | GSK embarks on Pennsylvania manufacturing expansion worth up to $800M, creating 200 new jobs | ||
| 24.10. | CDC unleashes 'Wild to Mild' campaign again to boost flu vaccination rates | ||
| 24.10. | Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
